Cyclophosphamide-based regimens are front-line treatment for numerous pediatric malignancies, however current dosing methods result in considerable interpatient variability in tumor response and toxicity. In this pediatric population, our objectives were to 1. quantify and explain the pharmacokinetic variability of cyclophosphamide, and two of its metabolites, hydroxycyclophosphamide (HCY) and carboxyethylphosphoramide mustard (CEPM); 2. apply a population pharmacokinetic model to describe the disposition of cyclophosphamide and these metabolites. A total of 196 blood samples were obtained from 22 children with neuroblastoma receiving intravenous (IV) cyclophosphamide (400 mg/m 2 /day) and topotecan. Blood samples were quantitated for concentrations of cyclophosphamide, HCY and CEPM using liquid chromatography-mass spectrometry and analyzed using nonlinear mixed effects modeling with NONMEM software system. After model building was complete, the area under the concentration-time curve (AUC) was computed using NONMEM. Cyclophosphamide elimination was described by noninducible and inducible routes with the latter producing HCY.
INTRODUCTION
Cyclophosphamide is the cornerstone of curative chemotherapy regimens in over 50% of newly diagnosed pediatric cancer patients. Dose intensification of cyclophosphamide is associated with improved outcome in many of these patients, but is also associated with increased adverse drug reactions (ADRs). The pressing need for improving the safety of cyclophosphamide is highlighted by the impact of a minor dosing modification to the VAC (vincristine/dactinomycin/cyclophosphamide) regimen leading to unexpected increase in ADRs in children less than 3 years old. 1 Thus, there is a need to delineate factors in cyclophosphamide metabolism that may impact both response and ADRs to cyclophosphamidebased combination chemotherapy regimens. In adults, there is substantial interpatient variability in the cyclophosphamide area under the plasma concentration-time curve (AUC), and an even greater variability in the AUC of its metabolites when cyclophosphamide is dosed based on body surface area (BSA) or weight. 2, 3 Children have more rapid cyclophosphamide clearance normalized to BSA (i.e., ml/min/m 2 ) relative to adults, although the mechanism is unidentified. [4] [5] [6] [7] [8] Cyclophosphamide predominantly undergoes hepatic elimination, with 25% (range 5-30%) of an IV dose excreted unchanged in the urine. 3 A major fraction of cyclophosphamide dose (70%) is metabolized to hydroxycyclophosphamide (HCY) by multiple cytochrome P450
enzymes. 3 A minor fraction of cyclophosphamide dose (5%) is metabolized to dechloroethylcyclophosphamide (DCCY) by CYP3A4/5. 9 The metabolite HCY exists in equilibrium with its tautomer-aldophosphamide, and the concentrations of these two metabolites are assayed together. 10 HCY undergoes intracellular transport, subsequently releasing phosphoramide mustard which covalently cross-links DNA. Phosphoramide mustard does not readily cross cell membranes and thus makes the transport of HCY critical. 3 Hydroxycyclophosphamide is metabolized by aldehyde dehydrogenase 1A1 (ALDH1A1) to nontoxic carboxyethylphosphoramide mustard (CEPM). 3 CEPM is the predominant urinary metabolite of cyclophosphamide. 3 A substantial challenge in seeking a better understanding of cyclophosphamide pharmacokinetics and pharmacodynamics has been the difficulty in quantitating HCY plasma concentrations. 10 HCY is extremely unstable in biologic fluids (in vitro half-life in plasma < 3 minutes) and only recently have more clinically applicable methods been developed. [11] [12] [13] [14] These methods are accurate, sensitive and specific and have since provided reliable tools to advance our understanding of the pharmacokinetic/dynamics of cyclophosphamide and its metabolites in predominantly adult patients receiving myeloablative dose cyclophosphamide prior to hematopoietic cell transplantation. 2, [15] [16] [17] [18] [19] In this study, we sought to be the first to characterize HCY pharmacokinetics and to develop a population pharmacokinetic model of cyclophosphamide, HCY, and CEPM in children receiving multiple daily doses of cyclophosphamide.
METHODS
Patient population. Twenty-two children (17 male and 5 female) were included in this study.
The pharmacokinetics were evaluated after the first cycle of fractionated non-myeloablative dose cyclophosphamide with topotecan, administered under a limited institution pilot protocol, and University of California San Francisco (San Francisco, CA). Children from the Children's
Hospital at Westmead could participate in the clinical trial but were excluded from the cyclophosphamide pharmacokinetic study due to the extended time period (i.e., >48 hours (h)) necessary to transport the plasma samples from Australia to the United States. Prior to study conduct, parental written informed consent was obtained for all children and written assent for those children over 7 years of age was obtained.
All children were diagnosed with neuroblastoma or ganglioneuroblastoma and had no prior systemic therapy. All children had adequate renal (i.e., serum creatinine < 1.5 mg/dL, and creatinine clearance or radioisotope glomerular filtration rate (GFR) > 60 ml/min/1.73 m²) and liver (i.e., total bilirubin < 1.5 mg/dL and alanine aminotransferase < 300 units/L) function. Prior to chemotherapy administration, radioisotope GFR was determined using each individual institution's procedures.
Chemotherapy regimen.
Cyclophosphamide was infused through a central venous access catheter over 30 minutes at a dose of 400 mg/m 2 /day in those children weighing greater than 12 kilograms or 13.3 mg/kg/day in those children weighing 12 kilograms or less. The body weight and BSA used to calculate doses were based on individual institutional guidelines.
Cyclophosphamide was administered daily for 5 days. Cyclophosphamide doses were not adjusted based on pharmacokinetic data. Immediately after each cyclophosphamide infusion was completed, a 30-minute topotecan infusion began and was repeated daily after each dose of cyclophosphamide. Topotecan doses were pharmacokinetically targeted after doses 1 and 3.
The success of topotecan targeting and clinical response will be reported in a separate manuscript.
Cyclophosphamide pharmacokinetic sampling and analysis. The blood volume for cyclophosphamide pharmacokinetic analysis was limited by the young age of the patient population and the blood volume needed for pharmacokinetically targeting topotecan doses.
Cyclophosphamide pharmacokinetic blood samples were drawn from the lumen not used to infuse the cyclophosphamide dose. Pharmacokinetic blood samples were drawn immediately before, upon completion of the 30-minute infusion, and at 3, 6, and 24 h after the start of the first and fourth cyclophosphamide infusions. The volume of blood drawn was 1 mL for the first four samples and 2 mL for the fifth sample (i.e., 24 h post infusion).
The sample processing procedures were derived from those developed in hematopoietic cell transplant recipients. 13, 14 Aliquots of each sample were placed into tubes containing either phenylhydrazine for analysis of HCY or ethylenediaminetetraacetic acid for analysis of cyclophosphamide and CEPM. The tubes were inverted 3 to 4 times, stored at 4°C for a maximum of 1 h and centrifuged. The supernatant was then decanted and stored at -70°C within 1 h of sample collection.
All samples were shipped on dry ice to our laboratory within 3 months.
Cyclophosphamide, HCY, and CEPM concentrations in plasma were quantitated separately using the methods of Kalhorn et al 13, 14 with minor modifications as described in Table 1 . In the case of CEPM, negative ion detection at m/z 293 was used. This ion, although lesser in abundance, has a lower incidence of background interference, allowing for more sensitive detection of CEPM. The HCY-phenylhydrazine derivative was detected in the negative ion mode as the chloride adduct at m/z 401.
14 Population Pharmacokinetic Modeling. Given the small number of blood samples available in each subject, nonlinear mixed effects modeling was used to describe this pharmacokinetic dataset. The nonlinear mixed effects approach explicitly models the time course of the data and the hierarchical statistical variability which is present among subjects and within subjects. The pharmacokinetic model framework we used is depicted in Figure 1 and its components have been previously described. 18, 21 The definition of the different parameters of this model is explained in Table 3 
respectively and where the model parameters are described in Figure 1 and Table 3 . The model departed from that of Qiu and Yao et al 21 in the following ways. First, doses were based upon BSA rather than body weight (see "Chemotherapy Regimen" section above). In those two children whose cyclophosphamide dose was based upon weight, the actual dose (mg) administered was divided by that patient's BSA. Weight and BSA are correlated in this pediatric population (r 2 =0.97), and thus we would expect similar results using weight-normalized dosing. Second, we made no assumption regarding the influence of the covariate age upon the base model. Third, the volume of distribution of HCY (V HCY ) and CEPM (V CEPM ) were both assumed based on our previous experience with cyclophosphamide modeling in hematopoietic cell transplant recipients. 21, 23 . In our previous cyclophosphamide modeling, V HCY and V CEPM could not be estimated 23 and a value of 1 L was assumed for adults. 21, 23 The average BSA in the original hematopoietic cell As a validation of the model, we performed a visual predictive check wherein data were simulated for 4400 subjects (200 for each of the 22 measured covariate sets) using the final population pharmacokinetic model and the median and 90% prediction intervals plotted with the original data.
Statistical Analysis.
Generalized estimating equations were used to evaluate the association of AUC with independent variables that included age, sex, BSA, GFR and day of CY administration. Each analysis was done separately for the AUCs of CY, HCY, and CEPM. SAS Version 9.1 (Cary, NC) was used for all statistical analyses. Quantitation of cyclophosphamide and metabolites. Twenty two and twenty patients, respectively, had pharmacokinetic sampling after the first and fourth cyclophosphamide dose.
RESULTS

Patient
Cyclophosphamide and CEPM concentrations were detectable in 167 (85%) and 128 (65%), respectively, of 196 samples. HCY required separate bedside processing, and was detectable in 113 of 196 (58%) samples. The majority of samples which were below the limit of detection were the 24 h samples, despite obtaining 2 ml of blood in an effort to improve our ability to quantitate cyclophosphamide, HCY and CEPM. Of the 29 samples drawn at 24 h, no analytes could be quantitated in 23 samples, 5 had one analyte that was detectable and 1 was drawn after the subsequent dose was given (the latter of which was deleted from population pharmacokinetic modeling).
Population pharmacokinetic modeling. In Model 1 (see Table 2 Various alternative models were evaluated, and the results are summarized in Table 2 . In Model 3, we replaced the fixed-effects model for parameter V CY with a mixed-effects model with lognormal random effect. This resulted in a highly significant improvement in OFV Table 4 for the whole patient population. covariates (e.g., GFR). Improved understanding of the determinants of variability can then lead to improved trial design. While the awareness of these issues has increased for drugs in the development phase, there is a still strong need to improve dosing for drugs that are already in use, such as cyclophosphamide. Understanding the sources of variability in young patients is of the utmost importance to optimize exposure to anti-tumor chemotherapy to ultimately achieve the maximum disease response with non-lethal toxicity. In addition, a population pharmacokinetic model facilitates development of an improved limited sampling schedule, which could decrease the needed blood volume and resource intensity of pharmacokinetic-linked pharmacodynamic trials. 27 Cyclophosphamide clearance agrees with the previously published values in pediatric populations ( Table 5 ), suggesting that topotecan does not influence cyclophosphamide elimination. 4, [6] [7] [8] Similarly, the autoinduction of cyclophosphamide clearance (resulting in decreased AUC for subsequent doses) agreed with previous reports. 17, [28] [29] [30] In addition, the current convention of dosing children less than 12 kg on a mg/kg basis (i.e., patients 2 and 19) appears to yield a comparable AUC to those larger children (i.e., >12 kg) who receive cyclophosphamide 400 mg/m 2 ( Table 4 ). The latter point is critically important, as children younger than 3 years of age experienced increased ADRs after what was anticipated to be a minor dosing modification to the VAC (vincristine/dactinomycin/cyclophosphamide) regimen. 1 These pharmacokinetic data, along with the accompanying population pharmacokinetic model, represent initial steps towards the goal of optimizing cyclophosphamide dosing in such young children.
Using analytical methods developed for pharmacodynamic studies in myeloablative hematopoietic cell transplant patients (Table 1) , we are the first to describe the pharmacokinetics of HCY in children. The interpatient variability in the AUC of HCY was substantial, that is 5.6 fold after dose 1 and 3.8 fold after dose 4 (Table 4) . A similar trend was found in the AUC of CEPM (Table 4) . In contrast to the reports of Yule et al that some children had no detectable CEPM concentration, 4, 5, 7, 8 we were able to estimate the AUC of CEPM in all patients (Table 5 ) due to the increased sensitivity of our analytical method (Table 1 ) and the use of a population pharmacokinetic model (Figure 1) . Notably, there was a weak correlation between the AUC of CY and the AUC of its metabolites, in agreement with previous reports. 12, 16, 17, 31, 32 This suggests that the cyclophosphamide clearance (as AUC = dose/clearance) cannot be used to predict metabolite exposure as has been suggested. 8, 33, 34 This is the first population pharmacokinetic model of cyclophosphamide and metabolite disposition in young children, specifically less than 10 years of age (i.e., 1.30 -9.37 years). The majority of the population pharmacokinetic models were presumably (i.e., age not reported) 35 or were exclusively from 36 populations older than 10 years of age. However, our initial population pharmacokinetic model of cyclophosphamide in hematopoietic cell transplant patients receiving myeloablative dose cyclophosphamide (60 mg/kg/day × 2 days) with total body irradiation (CY/TBI) did include eight children whose age were less than 10 years old. 21 In the CY/TBI population, age was the only covariate which improved model fitting and was inversely correlated with the noninducible clearance (CL NON ) of cyclophosphamide. 21 In agreement with this finding, the CL NON in the neuroblastoma patients was higher (i. GFR was a covariate for the fractional elimination of HCY and its conversion to CEPM (Tables 2 and 3 ). Further studies are needed to confirm these findings, as a physiologic rationale for GFR being a covariate with these two parameters is currently elusive. CEPM is the predominant urinary metabolite after cyclophosphamide administration and its AUC was dramatically higher in an anephric child. 38 The pharmacokinetic model needs to be validated in a separate pediatric population, especially due to our limited ability to quantitate all three analytes in many of the 24h samples. We plan to validate this model in a separate cohort of children receiving non-myeloablative dose cyclophosphamide and subsequently create an optimal limited sampling schedule to conduct pharmacokinetic and pharmacodynamic studies in children. Identifying pharmacodynamic relationships in future studies could lead to personalized cyclophosphamide dosing to achieve a target AUC to improve efficacy or decrease toxicity. We are currently employing this approach after myeloablative cyclophosphamide dosing in hematopoietic cell transplant recipients.
Pharmacodynamic studies are needed to determine the clinical relevance of this interpatient variability in the pharmacokinetics. Quantitation of cyclophosphamide and CEPM concentrations allowed for comparison to historical cyclophosphamide pharmacokinetic data within pediatric patients. It is also important to quantitate CEPM concentrations because elevated CEPM AUC is associated with a higher risk of liver toxicity in hematopoietic cell transplant recipients receiving myeloablative dose CY/TBI. 2 Quantitation of HCY was critical, as its pharmacokinetics has been reported in only one anephric child to date. 38 The majority of pharmacodynamic studies with cyclophosphamide and its metabolites have been conducted in patients receiving myeloablative cyclophosphamide for conditioning prior to hematopoietic cell transplantation. 2, 15, 31 In this population, the pharmacodynamics of cyclophosphamide and its metabolites differ based on the conditioning regimen. 31 In those receiving busulfan/cyclophosphamide, the AUC of cyclophosphamide, HCY and CEPM are not related to toxicity or response. 31 However, in patients receiving CY/TBI, an elevated AUC of CEPM is associated with a higher risk of liver toxicity. 2 This has led to ongoing studies of targeting cyclophosphamide doses based on the AUC of CEPM in hopes of lowering toxicity while maintaining the AUC of HCY in hopes of maintaining engraftment rates. 18 These results suggest that the concentration -effect relationships may differ between combination chemotherapy regimens and thus, future pharmacokinetic and pharmacodynamic studies should be conducted in homogeneous disease populations treated with the same combination 
